XML 22 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Capital in Excess of Par Value
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive (Loss) Income
Accumulated Other Comprehensive (Loss) Income
Cumulative Effect, Period of Adoption, Adjustment
Beginning Balance (in shares) at Oct. 28, 2017 [1]     368,636,000          
Beginning Balance at Oct. 28, 2017 [1]     $ 61,441 $ 5,250,519 $ 5,179,024   $ (61,359)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net Income [1]         1,506,980      
Dividends declared per share (USD per share) $ 1.89              
Dividends declared and paid         (703,307)      
Issuance of stock under stock plans and other (in shares)     4,012,000          
Issuance of stock under stock plans and other     $ 668 98,359        
Tax benefit — equity based awards       7,741        
Stock-based compensation expense       151,165        
Other comprehensive Income (loss)             2,919  
Common stock repurchased (in shares)     (2,488,000)          
Common stock repurchased     $ (415) (225,562)        
Ending Balance (in shares) at Nov. 03, 2018 [1]     370,160,000          
Ending Balance at Nov. 03, 2018     $ 61,694 [1] 5,282,222 [1] 5,982,697 [1] $ 331,026 (58,440) [1]  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net Income         1,363,011      
Dividends declared per share (USD per share) $ 2.10              
Dividends declared and paid         (777,481)      
Issuance of stock under stock plans and other (in shares)     4,271,000          
Issuance of stock under stock plans and other     $ 712 115,811        
Stock-based compensation expense       150,300        
Other comprehensive Income (loss)             (129,359)  
Common stock repurchased (in shares)     (6,129,000)          
Common stock repurchased     $ (1,021) (611,984)        
Ending Balance (in shares) at Nov. 02, 2019     368,302,000          
Ending Balance at Nov. 02, 2019 $ 11,709,188   $ 61,385 4,936,349 6,899,253 2,379 (187,799) $ (2,379)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Accounting Standards Update [Extensible List] us-gaap:AccountingStandardsUpdate201616Member              
Issuance of stock as charitable contribution (in shares)     335,654          
Issuance of stock as charitable contribution $ 40,000              
Beginning Balance (in shares) at Nov. 02, 2019     368,302,000          
Beginning Balance at Nov. 02, 2019 $ 11,709,188   $ 61,385 4,936,349 6,899,253 $ 2,379 (187,799) $ (2,379)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net Income         1,220,761      
Dividends declared per share (USD per share) $ 2.40              
Dividends declared and paid         (886,155)      
Issuance of stock under stock plans and other (in shares)     3,110,000          
Issuance of stock under stock plans and other     $ 518 67,885        
Issuance of stock as charitable contribution (in shares)     336,000          
Issuance of stock as charitable contribution     $ 56 39,944        
Stock-based compensation expense       149,518        
Other comprehensive Income (loss)             (59,283)  
Common stock repurchased (in shares)     (2,263,000)          
Common stock repurchased     $ (377) (244,110)        
Ending Balance (in shares) at Oct. 31, 2020     369,485,000          
Ending Balance at Oct. 31, 2020 $ 11,997,945 $ (2,379) $ 61,582 $ 4,949,586 $ 7,236,238   $ (249,461)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Accounting Standards Update [Extensible List] us-gaap:AccountingStandardsUpdate201802Member              
[1] Balances have been restated to reflect the adoption of Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (ASU 2014-09). See Note 2a, Principles of Consolidation, of the Notes to Consolidated Financial Statements.